Skip to main content

FGFR Gene Alteration clinical trials at UCSD

3 in progress, 1 open to eligible people

Showing trials for
  • ICP-192 in Patients With Advanced Solid Tumors

    open to eligible people ages 18 years and up

    This is a multi-center, open-label, phase I/II clinical study to evaluate ICP-192 in patients with advanced solid tumors and FGFR gene alterations. It consists of two parts: Part I (Phase I), dose escalation and Part II (Phase II), dose expansion.

    La Jolla, California and other locations

  • KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations

    Sorry, in progress, not accepting new patients

    The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of KIN-3248, an oral small molecule FGFR inhibitor, in adults with advanced tumors harboring FGFR2 and/or FGFR3 gene alterations.

    La Jolla, California and other locations

  • Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement

    Sorry, not currently recruiting here

    This is an open-label, multinational, randomized Phase 2 study confirming the clinical benefit of 20 mg futibatinib and evaluating the safety and efficacy of 16 mg futibatinib in previously treated CCA harboring FGFR2 gene fusions and other rearrangements.

    La Jolla, California and other locations

Our lead scientists for FGFR Gene Alteration research studies include .

Last updated: